Abstract 3565
Background
Pooled analyses from 2 phase III trials of patients (pts) with metastatic breast cancer (mBC) treated with eribulin (E) versus other chemotherapy showed improved overall survival (OS) favoring E. Subsequent subgroup analyses, including pts with visceral metastases (VM), also showed improved OS when treated with E. Current 3rd line mBC chemotherapy options include E, gemcitabine (G) and capecitabine (C), among others. This study evaluated 1-year (yr) OS in a real world setting among mBC pts with VM treated with E, G, or C in a US cancer center network.
Methods
This retrospective study investigated pts with mBC with biopsy proven VM (liver and/or lung), treated with E, G, or C in 3rd line chemotherapy from 1/1/2012 to 11/1/2018. Electronic health records and cancer registry data were used to detect differences in OS (number of mons from start of 3rd line until death). Univariate and multivariate analyses of 1-yr survival between E, G, and C were conducted using Kaplan Meier (KM) and Cox proportional hazard (CPH) models respectively.
Results
Of 1,828 mBC pts, 1,417 had VM, and 443 (27.5% triple negative, 13.7% HER2+ and 51.9% ER+/PR+) received 3rd line therapy with E = 229 (51.7%), G = 134 (30.2%) or C = 80(18.1%). On average, E, G, and C pts did not differ by age, ethnicity, BMI or ECOG score (categorized as good [0-1] and poor [>2]), but E pts had higher mean income compared to G or C. 1-yr KM survival analyses included 370 pts (n = 195 E, 117 G, and 58 C) with at least 1-yr follow up. 150 patients (45% E, 33% G, and 41% C) were alive at the end of 1-yr. Survival curves between E, G, and C differed significantly (Logrank p < 0.05; Wilcoxon p < 0.05). Censored median survival of E pts was 9.75 mons compared to 6.95 for G (p < 0.05) and 7.48 for C pts, respectively. CPH analysis adjusted for age, ethnicity, ECOG score, BMI, and adverse events showed significant survival benefit for E pts compared to G (HR = 0.71, p < 0.05), but no significant differences between E vs C or C vs G pts.
Conclusions
This real-world 1-yr survival analysis of pts with mBC and VM demonstrated significantly better OS for pts receiving E as compared to G, and a trend favoring OS for patients receiving E in comparison to C.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Eisai Inc.
Funding
Eisai Inc.
Disclosure
S.M. Kazmi: Speaker Bureau / Expert testimony: Eisai, Takeda, Lilly, Merck; Advisory / Consultancy: Merck, Takeda. E. Wang: Non-remunerated activity/ies, Eisai employee at the time of research: Eisai. R.S. Hauser: Research grant / Funding (institution): Eisai. P.A. Kaufman: Advisory / Consultancy, Research grant / Funding (institution), research grant support, and consulting fees: Eisai. All other authors have declared no conflicts of interest.
Resources from the same session
3716 - Prognostic factors for predicting early recurrence within the first year of surgery in pancreatic ductal adenocarcinoma
Presenter: Naru Kim
Session: Poster Display session 2
Resources:
Abstract
3947 - Integrated population pharmacokinetic modelling of liposomal irinotecan in patients with various tumour types, including untreated metastatic pancreatic cancer (mPC)
Presenter: Teresa Macarulla
Session: Poster Display session 2
Resources:
Abstract
2880 - Expression of long noncoding RNA and clinical outcomes of pancreatic cancer patients who received adjuvant chemotherapy by S-1 or GEM after curative resection.
Presenter: Mariko Kamiya
Session: Poster Display session 2
Resources:
Abstract
5029 - POLO: Time to treatment discontinuation and subsequent therapies following maintenance olaparib for patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC)
Presenter: Eric Van Cutsem
Session: Poster Display session 2
Resources:
Abstract
4730 - Diagnostic Value of Digital Multiplexed Detection of Single Nucleotide Variants in Pancreatic Cancer Specimens Collected by Endoscopic Ultrasound Fine-Needle Aspiration
Presenter: Irina Cazacu
Session: Poster Display session 2
Resources:
Abstract
3303 - Phase I/II study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer
Presenter: Esther Pijnappel
Session: Poster Display session 2
Resources:
Abstract
2009 - Efficacy of platinum-containing chemotherapy and prognosis of pancreatic cancer patients with homologous recombination deficiency: meta-analysis of published clinical studies
Presenter: Elizeveta Polyanskaya
Session: Poster Display session 2
Resources:
Abstract
2164 - Plasmatic CXCL8 is a marker for TGFß-activated kinase 1 (TAK1) activation which may predict resistance to nanoliposomal irinotecan (nal-IRI) in gemcitabine-refractory pancreatic cancer (PC) patients
Presenter: Valeria Merz
Session: Poster Display session 2
Resources:
Abstract
2529 - A protein level signature of four selected genes associated with survival outcomes of patients with pancreatic ductal adenocarcinoma
Presenter: Jie Hua
Session: Poster Display session 2
Resources:
Abstract
4947 - Pre-treatment serum 25-hydroxyvitamin D levels and survival in a Danish cohort of patients with pancreatic cancer
Presenter: Louise Rasmussen
Session: Poster Display session 2
Resources:
Abstract